Shop
eStoreRx™
Online Supplement Dispensary
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
This inclusive membership contains all of the the tools you need to grow your business, including WholeLifeRx™, Nimativ®, WholeLifeQ™, eStoreRx™ and Practice Success Programs.
Easy direct-to-patient ordering & fulfilment for Lifelong Wellness, eStoreRx™ is offered as part of the WholePractice membership or as a stand-alone program.
April 18 2024
Results of a large population-based observational cohort study examining the association between weight loss and diabetes remission were recently publ...
In a population-based Taiwanese study of those taking proton pump inhibitors (PPIs), the long-term safety of PPI-associated chronic kidney disease (CKD) and kidney injury was evaluated, as it is viewed as a significant concern in these patients. The use of PPIs predisposed these individuals to a 1.4-fold higher odds of CKD, as compared to those who never used PPIs. The study also recognized that “almost all major types of PPIs present a weak association with increased odds of CKD in cumulative duration and dosage regression analysis.” Thus, according to this evaluation, the use of proton pumpinhibitors correlated with an increased risk of chronic kidney disease, as an elevated risk of acute kidney injury was demonstrated in these individuals. [“The OR for CKD was 1.41 for subjects using PPIs [95% confidence interval (CI) 1.34, 1.48] compared with subjects who had never used PPIs. The OR in relation to cumulative duration (per month) of PPIs use was 1.02 (95% CI 1.01, 1.02) and the OR in relation to cumulative dosage (per microgram) of PPIs use was 1.23 (95% CI 1.18, 1.28).”]
Hung S-C, Liao K-F, Hung H-C, Lin C-L, Lai S-W, Lee P-C, Hung S-R. Using proton pump inhibitors correlates with an increased risk of chronic kidney disease: a
nationwide database-derived case-controlled study. Family Practice. 14 October 2017 cmx102, https://doi.org/10.1093/fampra/cmx102.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment